# LYPD2

## Overview
LYPD2 is a gene that encodes the protein LY6/PLAUR domain containing 2, which is a member of the Ly6/uPAR family. This family is characterized by the presence of a LU domain, known for its three-fingered folding topology and structural similarity to snake venom toxins, although it is non-toxic in humans (Loughner2016Organization; Leth2019Evolution). The LYPD2 protein is typically anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, allowing it to localize to lipid rafts and potentially interact with other cell surface proteins (Loughner2016Organization). Despite its structural features, LYPD2 does not interact with GluR2 AMPA receptor subunits, suggesting it may have other cellular roles (Lauriello2022GluR2Q). Clinically, LYPD2 has been associated with altered expression in immune cells lacking the Y chromosome and is linked to survival outcomes in childhood acute myeloid leukemia, indicating its potential as a prognostic marker (Dumanski2021Immune; Zhang2019&lt; p&gt; A). Further research is needed to elucidate its full range of functions and clinical implications.

## Structure
The LYPD2 protein is a member of the Ly6/uPAR family, characterized by the presence of a LU domain. This domain typically features a three-fingered folding topology, with three long loops projecting from a disulfide-rich core, forming a central β-sheet (Loughner2016Organization; Leth2019Evolution). The LU domain is composed of 60-90 amino acid residues and is stabilized by specific disulfide bonds, which are crucial for maintaining the protein's structural integrity (Loughner2016Organization; Leth2019Evolution).

The LYPD2 protein, like other members of its family, may be anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, which is encoded by the third exon of its gene (Loughner2016Organization). This anchoring allows the protein to localize to lipid rafts on the cell surface, facilitating interactions with other proteins (Loughner2016Organization). The LU domain's structural motif is evolutionarily related to snake venom toxins, although it is not toxic in humans (Upadhyay2019Emerging).

Post-translational modifications such as glycosylation and disulfide bond formation are common in the Ly6/uPAR family, influencing the stability and function of the proteins, including LYPD2 (Loughner2016Organization). However, specific details on the primary, secondary, tertiary, and quaternary structures of LYPD2 are not provided in the available context.

## Clinical Significance
The LYPD2 gene has been implicated in various clinical contexts due to its altered expression levels. In immune cells lacking the Y chromosome (LOY), LYPD2 is significantly overexpressed, with an 8.6-fold increase in transcript abundance. This dysregulation is part of a broader pattern affecting 489 autosomal genes, which may have implications for immune function and disease risk, although the specific clinical outcomes are not detailed (Dumanski2021Immune; Dumanski2019Immune).

In the context of childhood acute myeloid leukemia (AML), LYPD2 is one of the genes associated with overall survival. It was identified among 17 genes significantly linked to survival outcomes, suggesting its potential role as a prognostic marker. However, it was not included in the final six-gene prognostic model used to classify patients into risk groups (Zhang2019&lt; p&gt; A).

The role of LYPD2 in other diseases or conditions, such as its involvement in signal transduction pathways or its potential impact on cancer and autoimmune diseases, requires further investigation. The current understanding of LYPD2's clinical significance is primarily based on its expression changes in specific pathological contexts.

## Interactions
The LYPD2 protein, a member of the Ly6/uPAR family, was investigated for potential interactions with GluR2 AMPA receptor subunits, specifically the GluR2 Q and GluR2 R isoforms. Despite the structural similarities of LYPD2 to other Ly6 proteins known to interact with ionotropic receptors, studies using co-immunoprecipitation experiments in HEK 293 cells found no evidence of interaction between LYPD2 and either GluR2 Q or GluR2 R isoforms. These findings suggest that LYPD2 does not participate in direct regulatory interactions with these AMPA receptor subunits (Lauriello2022GluR2Q).

The study used stargazin, a known interactor with GluR2, as a positive control to confirm the experimental conditions were suitable for detecting protein-protein interactions. The successful pulldown of stargazin validated the experimental setup, reinforcing the conclusion that LYPD2 does not interact with the GluR2 subunits under the conditions tested (Lauriello2022GluR2Q). This lack of interaction indicates that LYPD2 may have other targets or roles within the cellular environment that remain to be explored.


## References


[1. (Lauriello2022GluR2Q) Anna Lauriello, Quinn McVeigh, and Rou-Jia Sung. Glur2q and glur2r ampa subunits are not targets of lypd2 interaction. PLOS ONE, 17(11):e0278278, November 2022. URL: http://dx.doi.org/10.1371/journal.pone.0278278, doi:10.1371/journal.pone.0278278. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0278278)

[2. (Loughner2016Organization) Chelsea L. Loughner, Elspeth A. Bruford, Monica S. McAndrews, Emili E. Delp, Sudha Swamynathan, and Shivalingappa K. Swamynathan. Organization, evolution and functions of the human and mouse ly6/upar family genes. Human Genomics, April 2016. URL: http://dx.doi.org/10.1186/s40246-016-0074-2, doi:10.1186/s40246-016-0074-2. This article has 158 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-016-0074-2)

3. (Dumanski2019Immune) Immune cells lacking Y chromosome have widespread dysregulation of autosomal genes. This article has 4 citations.

[4. (Dumanski2021Immune) Jan P. Dumanski, Jonatan Halvardson, Hanna Davies, Edyta Rychlicka-Buniowska, Jonas Mattisson, Behrooz Torabi Moghadam, Noemi Nagy, Kazimierz Węglarczyk, Karolina Bukowska-Strakova, Marcus Danielsson, Paweł Olszewski, Arkadiusz Piotrowski, Erin Oerton, Aleksandra Ambicka, Marcin Przewoźnik, Łukasz Bełch, Tomasz Grodzicki, Piotr L. Chłosta, Stefan Imreh, Vilmantas Giedraitis, Lena Kilander, Jessica Nordlund, Adam Ameur, Ulf Gyllensten, Åsa Johansson, Alicja Józkowicz, Maciej Siedlar, Alicja Klich-Rączka, Janusz Jaszczyński, Stefan Enroth, Jarosław Baran, Martin Ingelsson, John R. B. Perry, Janusz Ryś, and Lars A. Forsberg. Immune cells lacking y chromosome show dysregulation of autosomal gene expression. Cellular and Molecular Life Sciences, 78(8):4019–4033, April 2021. URL: http://dx.doi.org/10.1007/s00018-021-03822-w, doi:10.1007/s00018-021-03822-w. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-021-03822-w)

[5. (Leth2019Evolution) Julie Maja Leth, Katrine Zinck Leth-Espensen, Kristian Kølby Kristensen, Anni Kumari, Anne-Marie Lund Winther, Stephen G. Young, and Michael Ploug. Evolution and medical significance of lu domain−containing proteins. International Journal of Molecular Sciences, 20(11):2760, June 2019. URL: http://dx.doi.org/10.3390/ijms20112760, doi:10.3390/ijms20112760. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20112760)

[6. (Upadhyay2019Emerging) Geeta Upadhyay. Emerging role of lymphocyte antigen-6 family of genes in cancer and immune cells. Frontiers in Immunology, April 2019. URL: http://dx.doi.org/10.3389/fimmu.2019.00819, doi:10.3389/fimmu.2019.00819. This article has 89 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2019.00819)